V
Vincenzo Brancaccio
Researcher at Casa Sollievo della Sofferenza
Publications - 63
Citations - 5624
Vincenzo Brancaccio is an academic researcher from Casa Sollievo della Sofferenza. The author has contributed to research in topics: Factor V Leiden & Thrombosis. The author has an hindex of 31, co-authored 62 publications receiving 5314 citations. Previous affiliations of Vincenzo Brancaccio include University of Foggia.
Papers
More filters
Journal ArticleDOI
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
Giovanna D'Andrea,Rosa Lucia D'Ambrosio,Rosa Lucia D'Ambrosio,Pasquale Di Perna,Pasquale Di Perna,Massimiliano Chetta,Massimiliano Chetta,Rosa Santacroce,Rosa Santacroce,Vincenzo Brancaccio,Vincenzo Brancaccio,Elvira Grandone,Elvira Grandone,Maurizio Margaglione,Maurizio Margaglione +14 more
TL;DR: Genetic variants of the VKORC1 gene locus modulate the mean daily dose of drug prescribed to acquire the target anticoagulation intensity and accounted for about a third of the interindividual variability in the present setting.
Journal ArticleDOI
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
Guido Finazzi,Roberto Marchioli,Vincenzo Brancaccio,Piercarla Schinco,Finn Wisløff,Jacek Musiał,F. Baudo,M. Berrettini,Sophie Testa,Armando D'Angelo,G. Tognoni,T Barbui +11 more
TL;DR: High‐intensity warfarin was not superior to standard treatment in preventing recurrent thrombosis in patients with APS and was associated with an increased rate of minor hemorrhagic complications.
Journal ArticleDOI
Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis
Lucio Amitrano,Maria Anna Guardascione,Vincenzo Brancaccio,Maurizio Margaglione,Francesco Manguso,Luigi Iannaccone,Elvira Grandone,A. Balzano +7 more
TL;DR: In this article, the authors studied all patients with portal vein thrombosis (PVT) and liver cirrhosis admitted to their Unit from January 1998 to December 2002 and found that the presence of the mutation 20210 of the prothrombin gene increased more than fivefold the risk of PVT.
Journal ArticleDOI
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry
Guido Finazzi,Vincenzo Brancaccio,Marco Moia,N. Ciavarella,M. Gabriella Mazzucconi,Piercarla Schinco,Marco Ruggeri,Enrico Pogliani,Gabriella Gamba,Edoardo Rossi,Francesco Baudo,Cesare Manotti,Armando D'Angelo,Gualtiero Palareti,Valerio De Stefano,M. Berrettini,Tiziano Barbui +16 more
TL;DR: The present study shows that previous thrombosis and ACA titer > 40 U are independent predictors of thromBosis; history of miscarriage or vascular disease is significantly associated with adverse pregnancy outcome; and hematological malignancies can develop during follow-up in patients with antiphospholipid antibodies.
Journal ArticleDOI
Coagulation disorders in liver disease.
TL;DR: Emerging evidence shows that sepsis further impairs hemostasis in patients with liver cirrhosis bleeding from esophageal varices, and the therapeutic approach to coagulative disorders is also discussed.